Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.47 |
| ▸ | WNT1 | P04628 | 13/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558622 | 0.85 | WNT1 (0.57) | GSK3BDYRK1AWNT1POLBABL1 | |
| SCHEMBL12361578 | 0.78 | POLB (0.46) | GSK3BDYRK1AWNT1POLBABL1 | |
| SCHEMBL10165890 | 0.74 | WNT3A (0.59) | GSK3BDYRK1AWNT1 | |
| SCHEMBL10165895 | 0.72 | DYRK1A (0.51) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL558193 | 0.71 | GSK3B (0.63) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL10165889 | 0.71 | MAPK8 (0.72) | GSK3BDYRK1AWNT1 | |
| SCHEMBL558696 | 0.69 | GSK3B (0.55) | GSK3BDYRK1AWNT1 | |
| SCHEMBL10165894 | 0.68 | DYRK1A (0.53) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL29337087 | 0.66 | EP300 (0.65) | — | |
| SCHEMBL558043 | 0.66 | DYRK1A (0.61) | GSK3BDYRK1AWNT1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | GSK3B 685/4885DYRK1A 1064/4885WNT1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.